Lunatus to bring BioQ Pharma products to Gulf region

California’s BioQ Pharma, Inc. is teaming up with Dubai-based pharmaceutical company Lunatus to distribute infusible drugs in the Gulf Cooperation Council (GCC) zone.

BioQ focuses on developing and commercializing large volumes of infusible pharmaceuticals, which Lunatus will be authorization to distribute in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates.

The two drugs that will be distributed to the region’s medical establishment are BioQ’s ropivacaine, a local anesthetic drug intended as a post-operation pain reliever, and propofol, which is used for patient sedation.

Lunatus Managing Director Lina Kouatly said the company is excited to work with BioQ Pharma on introducing new medical solutions to the Gulf region.

"BioQ Pharma's innovative infusion pharmaceutical products offer a highly differentiated mode of delivering infusible pharmaceuticals to patients,” Kouatly said. “We see significant utility in BioQ's ready-to-use pharmaceuticals and believe they will remove much of the burden and overhead associated with the time consuming steps normally associated with drug infusions."

BioQ Pharma Ppresident and CEO Josh Kriesel said Lunatus presents the perfect partner to sell the pharmaceuticals in the GCC.

"Lunatus' proven marketing team will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to the (Middle East and North Africa) region,” Kriesel said. “We are extremely excited to be expanding our worldwide network through such a distinguished partner."